Anticoagulation: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
(Redirecting to Anticoagulant)
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{subpages}}
#redirect [[Anticoagulant]]
{{editintro}}
==Adverse effects==
Patients aged 80 years or more may be especially susceptible to bleeding complications with a rate of 13 bleeds per 100 person-years.<ref name="pmid17515465">{{cite journal |author=Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S |title=Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation |journal=Circulation |volume=115 |issue=21 |pages=2689-96 |year=2007 |pmid=17515465 |doi=10.1161/CIRCULATIONAHA.106.653048}}PMID 17515465</ref>
 
Patients with cancer are more likely to have bleeding complications, especially if they have Stage III (regionally extensive) or IV (metastatic) cancer.<ref name="pmid12393647">{{cite journal |author=Prandoni P, Lensing AW, Piccioli A, ''et al'' |title=Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis |journal=Blood |volume=100 |issue=10 |pages=3484–8 |year=2002 |pmid=12393647 |doi=10.1182/blood-2002-01-0108}}</ref> Regardless of the extent of cancer, the risk of bleeding was less than the risk of recurrent [[embolism and thromboembolism]]:
 
 
 
{| class="wikitable"
|+ Rates of major bleeding and recurrent [[embolism and thromboembolism]] (VTE)
! colspan="2" rowspan="2" |  !! rowspan="2"| No cancer !! colspan="3" |  Cancer
|-
!  Stage I or II !! Stage III !! Stage IV
|-
| rowspan="2"| '''Major<br>bleeding''' || Events per<br>100 patient-years ||align="center"| 8.6 || align="center"|3.4 ||align="center"| 19.1 ||align="center"| 42.8
|-
|      Hazard ratio ||align="center"| 1 ||align="center"| 0.5 ||align="center"| 2.15 ||align="center"| 4.8
|-
| rowspan="2"|  '''Recurrent<br>VTE''' || Events per<br>100 patient-years  ||align="center"| 12.8 ||align="center"| 14.5 ||align="center"| 44.1 ||align="center"| 54.1
|-
|    Hazard ratio ||align="center"| 1 ||align="center"| 1.9 ||align="center"| 5.3 ||align="center"| 4.6
|-
|  colspan="6" align="right"| Adapted from Table 3 of Prandoni et al.<ref name="pmid12393647"/>
|}
 
==References==
<references/>
 
==See also==
* [[Anticoagulant]]
* [[Coagulation]]
 
==External links==
* [http://www.chestjournal.org/content/vol126/3_suppl/ The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines]

Latest revision as of 04:55, 25 January 2008

Redirect to:

Retrieved from "https://citizendium.org/wiki/index.php?title=Anticoagulation&oldid=30339"